[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590331":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":116,"collaborators":19,"id":118,"slug":19,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":19,"eligibilityCriteria":123,"healthyVolunteers":119,"sex":124,"minAge":125,"maxAge":19,"enrollmentInfo":126,"targetDuration":19,"studyType":129,"phases":130,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},{"fullName":5,"class":6},"Deciphera Pharmaceuticals, LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DCC-2812","EXPERIMENTAL","Participants will receive DCC-2812 in dose escalation manner per dosing regimen depending upon evolving pharmacokinetic (PK), pharmacodynamic, and safety data.",[13],"Drug: DCC-2812",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered orally",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Clinical Team","STUDY_DIRECTOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","888-724-3274","clinicaltrials@deciphera.com",[30,50,66,83,100],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Dana-Farber Cancer Institute","RECRUITING","Boston","Massachusetts","02215","United States",{"type":38,"coordinates":39},"Point",[40,41],-71.05977,42.35843,{"lat":41,"lon":40},[44,48],{"name":45,"role":26,"phone":46,"phoneExt":19,"email":47},"Bicky Thapa, MD","617-632-3000","bicky_thapa@dfci.harvard.edu",{"name":45,"role":49,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"facility":51,"status":32,"city":52,"state":53,"zip":54,"country":36,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"University of Michigan","Ann Arbor","Michigan","48109",{"type":38,"coordinates":56},[57,58],-83.74088,42.27756,{"lat":58,"lon":57},[61,64],{"name":19,"role":26,"phone":62,"phoneExt":19,"email":63},"800-865-1125","CancerAnswerLine@med.umich.edu",{"name":65,"role":49,"phone":19,"phoneExt":19,"email":19},"Ulka Vaishampayan, MD",{"facility":67,"status":32,"city":68,"state":69,"zip":70,"country":36,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Vanderbilt- Ingram Cancer Center","Nashville","Tennessee","37232",{"type":38,"coordinates":72},[73,74],-86.78444,36.16589,{"lat":74,"lon":73},[77,81],{"name":78,"role":26,"phone":79,"phoneExt":19,"email":80},"Vanderbilt- Ingram Cancer Center Clinical Trials Office (CTO)","1-800-811-8480","CTIP@VUMC.ORG",{"name":82,"role":49,"phone":19,"phoneExt":19,"email":19},"Brian Rini, MD",{"facility":84,"status":32,"city":85,"state":86,"zip":87,"country":36,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"NEXT Oncology, Austin","Austin","Texas","78758",{"type":38,"coordinates":89},[90,91],-97.74306,30.26715,{"lat":91,"lon":90},[94,98],{"name":95,"role":26,"phone":96,"phoneExt":19,"email":97},"Clinical Trial Navigator","737-610-5180","hwatson@nextoncology.com",{"name":99,"role":49,"phone":19,"phoneExt":19,"email":19},"Andrae Vandross, MD",{"facility":101,"status":32,"city":102,"state":86,"zip":103,"country":36,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"NEXT Oncology, San Antonio","San Antonio","78229",{"type":38,"coordinates":105},[106,107],-98.49363,29.42412,{"lat":107,"lon":106},[110,114],{"name":111,"role":26,"phone":112,"phoneExt":19,"email":113},"Jordan Georg","210-580-9521","jgeorg@nextoncology.com",{"name":115,"role":49,"phone":19,"phoneExt":19,"email":19},"Ildefonso Rodriguez Rivera, MD",{"type":117,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100590331",false,"NCT06966024","Study of DCC-2812 in Participants With Advanced Genitourinary Cancers","An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer","Key Inclusion Criteria:\n\n* Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer\n* Able to take oral medication\n* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements\n* Adequate organ function and electrolytes\n\nKey Exclusion Criteria:\n\n* Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812\n* Impaired cardiac function\n* Major surgery within 28 days of the first dose of study drug","ALL","18 Years",{"count":127,"type":128},60,"ESTIMATED","INTERVENTIONAL",[131],"PHASE1","This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced\u002Fmetastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.",[134,135,136],"Renal Cell Carcinoma","Urothelial Carcinoma","Castration-resistant Prostate Cancer",[138],"Advanced malignancies","2026-05-18",{"date":141,"type":142},"2026-05-20","ACTUAL",{"date":144,"type":142},"2025-08-27",{"date":146,"type":128},"2029-02",{"name":5,"class":6},5]